Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
15 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Colocci’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
Plans whose provider directory lists this clinician
Licensed to practise in California · since 2000 · expires 2027-10-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
Administration of chemotherapy into vein, 1 hour or less
68
$19,070
$141
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
126
$12,568
$66
Short return visit (20+ min)
55
$5,659
$80
New patient visit (45+ min)
26
$4,142
$159
Administration of additional new drug or substance into vein, 1 hour or less
20
$3,772
$69
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
14
$3,654
$78
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
33
$2,710
$38
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
20
$2,460
$21
Injection of additional new drug or substance into vein
45
$1,852
$16
Injection, zoledronic acid, 1 mg
80
$1,847
—None
Injection of drug or substance into vein
42
$1,615
$36
Administration of chemotherapy into vein, each additional hour
23
$1,503
$29
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
38
$1,262
$15
Office for the evaluation and management of established patient that may not require presence of healthcare professional
28
$976
$23
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
14
$927
$30
Injection of drug or substance under skin or into muscle
29
$576
$14
Injection, fosaprepitant, 1 mg
12
$380
—None
Injection, ondansetron hydrochloride, per 1 mg
26
$61
—None
Infusion, normal saline solution, 250 cc
90
$54
—None
Injection, dexamethasone sodium phosphate, 1 mg
25
$44
—None
Injection, diphenhydramine hcl, up to 50 mg
17
$19
—None
Who their Medicare patients are
500 Original Medicare patients in 2024. Average age 76 · Women 66% · Also on Medicaid 4% · Health risk score 1.37. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
The office billed $5,335,154, Medicare allowed $2,019,103 and paid $1,604,023; for 73,226 services of 111 kinds; $1,449,760 of it was for drugs given in the office and $154,264 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
Original Medicare by year
2024
500
73,226
76
1.37
$5,335,154
$1,604,023
2023
528
82,982
77
1.34
$5,507,691
$1,661,520
2022
442
50,959
77
1.51
$3,078,938
$937,402
2021
483
97,419
76
1.57
$5,463,746
$1,753,532
2020
439
83,203
76
1.56
$4,581,419
$1,466,672
2019
464
62,243
76
1.75
$3,694,175
$1,143,998
2018
466
58,715
75
1.65
$3,575,480
$1,204,375
2017
546
66,261
76
1.65
$4,400,349
$1,422,891
2016
523
54,699
76
1.48
$4,171,902
$1,231,791
2015
516
50,952
75
1.40
$4,234,491
$1,260,436
2014
497
52,562
75
1.30
$3,696,272
$976,345
2013
397
32,523
75
1.50
$2,747,828
$704,409
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 27 services
Original Medicare services billed in 2023
Injection, pembrolizumab, 1 mg
14
$215,639
—None
Injection, vedolizumab, intravenous, 1 mg
14
$160,348
—None
Long return visit (40+ min)
145
$66,505
$161
Administration of chemotherapy into vein, 1 hour or less
76
$26,564
$145
Leuprolide acetate (for depot suspension), 7.5 mg
30
$22,021
—None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
127
$15,211
$69
Return visit (30+ min)
96
$14,479
$118
Short return visit (20+ min)
85
$8,299
$75
New patient visit (60+ min)
37
$7,474
$202
Administration of additional new drug or substance into vein, 1 hour or less
18
$3,465
$71
New patient visit (45+ min)
21
$3,221
$153
Injection of additional new drug or substance into vein
48
$3,103
$17
Administration of chemotherapy into vein, each additional hour
34
$3,033
$30
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
11
$2,966
$80
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
34
$2,375
$37
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
23
$2,308
$22
Injection, zoledronic acid, 1 mg
73
$2,230
—None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
23
$2,175
$31
Office for the evaluation and management of established patient that may not require presence of healthcare professional
35
$954
$24
Injection of drug or substance under skin or into muscle
31
$777
$14
Injection of drug or substance into vein
19
$769
$37
Infusion into a vein for hydration, each additional hour
14
$216
$14
Injection, methylprednisolone sodium succinate, up to 125 mg
14
$70
—None
Injection, dexamethasone sodium phosphate, 1 mg
27
$63
—None
Injection, ondansetron hydrochloride, per 1 mg
22
$60
—None
Infusion, normal saline solution, 250 cc
81
$51
—None
Injection, diphenhydramine hcl, up to 50 mg
25
$44
—None
2022: 23 services
Original Medicare services billed in 2022
Long return visit (40+ min)
167
$73,146
$161
Administration of chemotherapy into vein, 1 hour or less
64
$16,740
$151
Leuprolide acetate (for depot suspension), 7.5 mg
31
$15,596
—None
Return visit (30+ min)
77
$12,653
$122
Short return visit (20+ min)
85
$9,538
$82
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
60
$6,303
$73
New patient visit (60+ min)
17
$3,566
$210
Administration of additional new drug or substance into vein, 1 hour or less
24
$2,846
$73
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
14
$2,657
$83
Administration of chemotherapy into vein, each additional hour
27
$2,137
$31
New patient visit (45+ min)
12
$1,770
$147
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
26
$1,638
$32
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
33
$1,632
$35
Injection of additional new drug or substance into vein
44
$1,596
$17
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
14
$1,321
$22
Injection, zoledronic acid, 1 mg
34
$866
—None
Injection of drug or substance into vein
16
$636
$40
Office for the evaluation and management of established patient that may not require presence of healthcare professional
18
$573
$24
Injection of drug or substance under skin or into muscle
22
$506
$14
Injection, fosaprepitant, 1 mg
12
$348
—None
Injection, dexamethasone sodium phosphate, 1 mg
28
$46
—None
Injection, diphenhydramine hcl, up to 50 mg
23
$34
—None
Injection, ondansetron hydrochloride, per 1 mg
27
$34
—None
2021: 31 services
Original Medicare services billed in 2021
Long return visit (40+ min)
167
$86,590
$167
Injection, denosumab, 1 mg
18
$48,250
—None
Injection, infliximab, excludes biosimilar, 10 mg
12
$44,073
—None
Administration of chemotherapy into vein, 1 hour or less
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
81
$13,430
$79
Return visit (30+ min)
78
$12,603
$114
Short return visit (20+ min)
75
$8,146
$81
New patient visit (60+ min)
33
$6,740
$204
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
47
$5,617
$34
Administration of additional new drug or substance into vein, 1 hour or less
30
$4,891
$78
Injection of additional new drug or substance into vein
62
$4,188
$18
Administration of chemotherapy into vein, each additional hour
40
$3,239
$33
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
40
$3,220
$35
Administration of additional new drug or substance into vein using push technique
13
$2,337
$67
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
19
$2,299
$23
Injection, fosaprepitant, 1 mg
20
$1,997
—None
New patient visit (45+ min)
13
$1,953
$150
Injection of drug or substance under skin or into muscle
54
$1,908
$14
Injection of drug or substance into vein
23
$1,569
$45
Injection, zoledronic acid, 1 mg
36
$1,520
—None
Injection, paclitaxel, 1 mg
19
$1,219
—None
Office for the evaluation and management of established patient that may not require presence of healthcare professional
35
$1,104
$24
Collection of blood sample from implanted device
13
$1,011
$30
Injection, carboplatin, 50 mg
14
$372
—None
Injection, dexamethasone sodium phosphate, 1 mg
53
$182
—None
Injection, ondansetron hydrochloride, per 1 mg
43
$99
—None
Injection, methylprednisolone sodium succinate, up to 125 mg
14
$72
—None
Injection, diphenhydramine hcl, up to 50 mg
33
$65
—None
2020: 27 services
Original Medicare services billed in 2020
Return visit (30+ min)
223
$57,927
$99
Injection, infliximab, excludes biosimilar, 10 mg
11
$42,276
—None
Injection, denosumab, 1 mg
17
$41,475
—None
Leuprolide acetate (for depot suspension), 7.5 mg
34
$33,317
—None
Administration of chemotherapy into vein, 1 hour or less
81
$27,729
$151
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
71
$10,450
$75
New patient visit (60+ min)
40
$7,591
$190
Administration of additional new drug or substance into vein, 1 hour or less
32
$6,637
$74
Long return visit (40+ min)
30
$4,710
$135
Administration of chemotherapy into vein, each additional hour
41
$4,672
$32
Injection, fosaprepitant, 1 mg
14
$3,290
—None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
40
$3,202
$33
Injection of additional new drug or substance into vein
61
$3,150
$17
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
38
$2,571
$33
Administration of additional new drug or substance into vein using push technique
16
$2,028
$63
Telephone medical discussion with physician, 21-30 minutes
11
$2,001
$105
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
19
$1,868
$23
Telephone medical discussion with physician, 11-20 minutes
19
$1,605
$73
Injection of drug or substance into vein
16
$1,330
$42
Injection of drug or substance under skin or into muscle
37
$1,306
$14
Injection, zoledronic acid, 1 mg
29
$1,170
—None
Office for the evaluation and management of established patient that may not require presence of healthcare professional
31
$1,089
$24
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
11
$705
—None
Injection, methylprednisolone sodium succinate, up to 125 mg
11
$130
—None
Injection, dexamethasone sodium phosphate, 1 mg
37
$100
—None
Injection, ondansetron hydrochloride, per 1 mg
38
$91
—None
Injection, diphenhydramine hcl, up to 50 mg
26
$34
—None
2019: 23 services
Original Medicare services billed in 2019
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
11
$81,808
—None
Injection, infliximab, excludes biosimilar, 10 mg
17
$73,242
—None
Return visit (30+ min)
265
$61,884
$96
Leuprolide acetate (for depot suspension), 7.5 mg
39
$48,200
—None
Administration of chemotherapy into vein, 1 hour or less
80
$25,480
$149
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
77
$11,853
$76
New patient visit (60+ min)
40
$7,636
$191
Administration of chemotherapy into vein, each additional hour
40
$3,652
$31
Long return visit (40+ min)
22
$2,923
$122
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
40
$2,894
$32
Administration of additional new drug or substance into vein, 1 hour or less
17
$2,163
$72
Injection of additional new drug or substance into vein
53
$2,124
$17
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
18
$2,033
$22
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
28
$1,968
$32
Injection, zoledronic acid, 1 mg
34
$1,733
—None
New patient visit (45+ min)
12
$1,720
$143
Office for the evaluation and management of established patient that may not require presence of healthcare professional
33
$1,233
$22
Injection of drug or substance into vein
24
$1,105
$41
Injection of drug or substance under skin or into muscle
26
$1,019
$17
Injection, carboplatin, 50 mg
13
$416
—None
Injection, dexamethasone sodium phosphate, 1 mg
39
$96
—None
Injection, ondansetron hydrochloride, per 1 mg
24
$84
—None
Injection, diphenhydramine hcl, up to 50 mg
22
$21
—None
2018: 29 services
Original Medicare services billed in 2018
Injection, rituximab, 100 mg
12
$120,356
—None
Injection, pegfilgrastim, 6 mg
15
$104,091
—None
Return visit (30+ min)
267
$64,151
$94
Injection, infliximab, excludes biosimilar, 10 mg
12
$53,866
—None
Leuprolide acetate (for depot suspension), 7.5 mg
29
$38,048
—None
Injection, denosumab, 1 mg
12
$31,754
—None
Administration of chemotherapy into vein, 1 hour or less
92
$31,234
$149
New patient visit (60+ min)
62
$11,077
$179
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
58
$9,706
$75
Administration of additional new drug or substance into vein, 1 hour or less
24
$4,619
$71
Long return visit (40+ min)
31
$4,230
$128
Administration of chemotherapy into vein, each additional hour
44
$3,764
$32
Injection of additional new drug or substance into vein
60
$3,451
$18
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
36
$2,721
$32
Administration of additional new drug or substance into vein using push technique
18
$2,627
$61
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
33
$2,365
$32
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
11
$1,568
—None
Injection, zoledronic acid, 1 mg
25
$1,561
—None
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
14
$1,521
$22
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
11
$1,508
$84
Injection of drug or substance under skin or into muscle
39
$1,379
$21
Office for the evaluation and management of established patient that may not require presence of healthcare professional
35
$975
$21
Collection of blood sample from implanted device
19
$926
$25
Injection of drug or substance into vein
16
$867
$48
Irrigation of implanted venous access drug delivery device
11
$468
$28
Infusion into a vein for hydration, each additional hour
11
$265
$14
Injection, dexamethasone sodium phosphate, 1 mg
49
$140
—None
Injection, ondansetron hydrochloride, per 1 mg
36
$72
—None
Injection, diphenhydramine hcl, up to 50 mg
26
$25
—None
2017: 30 services
Original Medicare services billed in 2017
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
11
$85,130
—None
Return visit (30+ min)
317
$72,146
$92
Injection, infliximab, excludes biosimilar, 10 mg
14
$67,935
—None
Leuprolide acetate (for depot suspension), 7.5 mg
40
$42,825
—None
Injection, denosumab, 1 mg
14
$39,285
—None
Administration of chemotherapy into vein, 1 hour or less
76
$22,416
$143
New patient visit (60+ min)
85
$15,649
$184
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
69
$11,899
$71
Long return visit (40+ min)
38
$6,215
$132
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
44
$3,097
$33
Administration of chemotherapy into vein, each additional hour
33
$3,011
$28
Injection of drug or substance under skin or into muscle
55
$2,993
$26
Injection of additional new drug or substance into vein
55
$2,969
$23
Administration of additional new drug or substance into vein, 1 hour or less
19
$2,528
$67
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
22
$2,470
$18
Injection of drug or substance into vein
27
$2,187
$59
Administration of additional new drug or substance into vein using push technique
17
$1,730
$64
Injection, zoledronic acid, 1 mg
22
$1,426
—None
Drawing of blood for a medical problem
11
$1,234
$103
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
22
$1,204
$31
Office for the evaluation and management of established patient that may not require presence of healthcare professional
47
$1,078
$20
Infusion into a vein for hydration, each additional hour
12
$846
$15
Collection of blood sample from implanted device
18
$772
$23
Transfusion of blood or blood products
13
$742
$35
Injection, carboplatin, 50 mg
12
$391
—None
Injection, dexamethasone sodium phosphate, 1 mg
48
$91
—None
Injection, ondansetron hydrochloride, per 1 mg
31
$56
—None
Infusion, normal saline solution, 250 cc
15
$51
—None
Injection, diphenhydramine hcl, up to 50 mg
24
$22
—None
Injection, furosemide, up to 20 mg
11
$12
—None
2016: 32 services
Original Medicare services billed in 2016
Injection, pegfilgrastim, 6 mg
23
$154,992
—None
Injection, infliximab, excludes biosimilar, 10 mg
24
$110,191
—None
Injection, rituximab, 100 mg
11
$81,544
—None
Return visit (30+ min)
295
$71,450
$92
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
11
$60,713
—None
Injection, denosumab, 1 mg
13
$38,067
—None
Administration of chemotherapy into vein, 1 hour or less
94
$30,856
$140
Leuprolide acetate (for depot suspension), 7.5 mg
25
$30,527
—None
New patient visit (60+ min)
69
$12,911
$187
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
53
$8,326
$71
Injection of additional new drug or substance into vein
72
$6,301
$23
Long return visit (40+ min)
27
$4,172
$130
Administration of additional new drug or substance into vein, 1 hour or less
27
$3,710
$64
Injection of drug or substance into vein
35
$2,936
$56
Administration of chemotherapy into vein, each additional hour
46
$2,891
$28
Injection of drug or substance under skin or into muscle
48
$2,585
$25
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
16
$2,374
$77
Injection, zoledronic acid, 1 mg
22
$2,193
—None
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
31
$2,105
$32
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
17
$1,626
$18
Administration of additional new drug or substance into vein using push technique
15
$1,592
$64
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
17
$1,133
$31
Collection of blood sample from implanted device
16
$1,074
$23
Transfusion of blood or blood products
21
$1,059
$34
Infusion into a vein for hydration, each additional hour
14
$691
$14
Office for the evaluation and management of established patient that may not require presence of healthcare professional
27
$667
$20
Injection, carboplatin, 50 mg
12
$505
—None
Injection, dexamethasone sodium phosphate, 1 mg
58
$169
—None
Injection, ondansetron hydrochloride, per 1 mg
40
$91
—None
Injection, furosemide, up to 20 mg
23
$86
—None
Infusion, normal saline solution, 250 cc
20
$60
—None
Injection, diphenhydramine hcl, up to 50 mg
24
$30
—None
2015: 35 services
Original Medicare services billed in 2015
Injection, pegfilgrastim, 6 mg
24
$161,156
—None
Injection, rituximab, 100 mg
18
$141,306
—None
Injection, infliximab, excludes biosimilar, 10 mg
19
$98,563
—None
Return visit (30+ min)
311
$85,000
$98
Administration of chemotherapy into vein, 1 hour or less
97
$41,058
$146
Leuprolide acetate (for depot suspension), 7.5 mg
29
$39,317
—None
New patient visit (60+ min)
72
$14,152
$197
Cyclophosphamide, 100 mg
14
$13,341
—None
Injection of additional new drug or substance into vein
80
$7,590
$24
Injection, docetaxel, 1 mg
11
$7,347
—None
Injection, zoledronic acid, 1 mg
35
$6,837
—None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
43
$6,433
$75
Administration of additional new drug or substance into vein, 1 hour or less
37
$6,133
$67
Long return visit (40+ min)
32
$5,285
$136
Injection of drug or substance into vein
43
$3,985
$61
Administration of additional new drug or substance into vein using push technique
20
$3,936
$67
Injection of drug or substance under skin or into muscle
49
$3,106
$27
Administration of chemotherapy into vein, each additional hour
43
$3,053
$30
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
32
$2,886
$34
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
11
$2,168
—None
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
11
$1,932
$80
New patient visit (45+ min)
11
$1,756
$160
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
25
$1,662
$32
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
16
$1,220
$19
Infusion into a vein for hydration, each additional hour
19
$1,174
$16
Collection of blood sample from implanted device
18
$1,137
$26
Transfusion of blood or blood products
19
$960
$38
Irrigation of implanted venous access drug delivery device
17
$868
$26
Office for the evaluation and management of established patient that may not require presence of healthcare professional
31
$782
$21
Injection, carboplatin, 50 mg
15
$613
—None
Injection, dexamethasone sodium phosphate, 1 mg
64
$226
—None
Injection, ondansetron hydrochloride, per 1 mg
44
$94
—None
Injection, furosemide, up to 20 mg
21
$44
—None
Infusion, normal saline solution, 250 cc
20
$43
—None
Injection, diphenhydramine hcl, up to 50 mg
30
$24
—None
2014: 30 services
Original Medicare services billed in 2014
Injection, pegfilgrastim, 6 mg
21
$128,692
—None
Injection, infliximab, excludes biosimilar, 10 mg
26
$80,388
—None
Injection, rituximab, 100 mg
11
$70,426
—None
Return visit (30+ min)
289
$70,223
$91
Administration of chemotherapy into vein, 1 hour or less
92
$30,305
$135
Leuprolide acetate (for depot suspension), 7.5 mg
21
$28,540
—None
Long return visit (40+ min)
76
$12,836
$130
Injection, zoledronic acid, 1 mg
19
$10,004
—None
New patient visit (60+ min)
43
$7,566
$176
Injection of additional new drug or substance into vein
72
$7,277
$22
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
42
$5,888
$69
Administration of additional new drug or substance into vein, 1 hour or less
27
$4,028
$63
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
23
$3,832
$75
Injection of drug or substance under skin or into muscle
58
$3,160
$25
Administration of chemotherapy into vein, each additional hour
38
$2,721
$28
Administration of additional new drug or substance into vein using push technique
19
$2,366
$62
Injection of drug or substance into vein
21
$2,145
$56
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
14
$1,263
$18
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
20
$1,243
$32
Drawing of blood for a medical problem
11
$1,227
$102
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
18
$1,111
$30
Injection, carboplatin, 50 mg
18
$907
—None
Infusion into a vein for hydration, each additional hour
14
$702
$15
Office for the evaluation and management of established patient that may not require presence of healthcare professional
31
$628
$18
Collection of blood sample from implanted device
12
$601
$21
Irrigation of implanted venous access drug delivery device
11
$586
$24
Transfusion of blood or blood products
11
$462
$36
Injection, dexamethasone sodium phosphate, 1 mg
55
$183
—None
Injection, ondansetron hydrochloride, per 1 mg
42
$108
—None
Injection, diphenhydramine hcl, up to 50 mg
23
$35
—None
2013: 22 services
Original Medicare services billed in 2013
Injection, infliximab, excludes biosimilar, 10 mg
17
$71,129
—None
Injection, pegfilgrastim, 6 mg
18
$70,924
—None
Return visit (30+ min)
248
$64,355
$90
Administration of chemotherapy into vein, 1 hour or less
73
$27,694
$144
Leuprolide acetate (for depot suspension), 7.5 mg
14
$18,092
—None
Zoldedronic acid 1mg
15
$15,414
$136
Injection, zoledronic acid (zometa), 1 mg
12
$13,280
—None
New patient visit (60+ min)
53
$9,715
$183
Long return visit (40+ min)
31
$5,590
$127
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
36
$5,049
$77
Administration of additional new drug or substance into vein, 1 hour or less
21
$3,784
$73
Injection of additional new drug or substance into vein
41
$3,186
$23
Administration of chemotherapy into vein, each additional hour
34
$2,923
$31
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
20
$2,481
$78
Injection of drug or substance under skin or into muscle
38
$2,076
$26
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
15
$1,225
$32
Transfusion of blood or blood products
17
$983
$36
Irrigation of implanted venous access drug delivery device
12
$730
$24
Office for the evaluation and management of established patient that may not require presence of healthcare professional
19
$360
$18
Injection, ondansetron hydrochloride, per 1 mg
33
$156
—None
Injection, dexamethasone sodium phosphate, 1 mg
37
$107
—None
Injection, furosemide, up to 20 mg
11
$47
—None
Drugs they prescribed that Part D paid
$2,143,922
Pharmacies billed $2,143,922 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (13 of 799) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
640 generic and 159 brand-name prescriptions · $2,143,922 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Largest Part D drug costs
Xtandi
43
$573,163
$13,329
Erleada
33
$485,111
$14,700
Tukysa
14
$342,006
$24,429
Ibrance
14
$242,035
$17,288
Creon
13
$33,872
$2,606
See all 17 drugs
Every Part D drug this clinician prescribed
Xtandi
43
$573,163
$13,329
Erleada
33
$485,111
$14,700
Tukysa
14
$342,006
$24,429
Ibrance
14
$242,035
$17,288
Creon
13
$33,872
$2,606
Abiraterone Acetate
32
$32,870
$1,027
Eliquis
14
$13,815
$987
Anastrozole
212
$3,759
$18
Exemestane
30
$3,570
$119
Tamoxifen Citrate
79
$1,732
$22
Dexamethasone
23
$676
$29
Diphenoxylate-Atropine
16
$563
$35
Letrozole
18
$510
$28
Prochlorperazine Maleate
40
$373
$9
Ondansetron
28
$291
$10
Prednisone
33
$253
$8
Potassium Chloride
24
$187
$8
Year by year
Part D prescribing by year
2024
799
174
2% (13)
20%
$2,143,922
2023
879
208
1% (11)
—None
$2,119,835
2022
729
164
—None
—None
$1,699,031
2021
878
160
4% (34)
24%
$1,985,091
2020
886
152
3% (28)
25%
$2,224,825
2019
850
144
2% (14)
23%
$2,432,889
2018
796
136
4% (28)
28%
$2,059,271
2017
810
155
7% (60)
26%
$1,564,666
2016
739
126
10% (77)
—None
$1,004,535
2015
758
139
9% (68)
23%
$967,569
2014
702
134
11% (80)
20%
$645,754
2013
761
119
13% (101)
—None
$528,553
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
Part D drugs prescribed in 2023
Xtandi
46
$476,897
$10,367
Erleada
26
$406,801
$15,646
Ibrance
23
$399,442
$17,367
Tukysa
12
$293,472
$24,456
Abiraterone Acetate
48
$117,571
$2,449
Anastrozole
219
$5,903
$27
Exemestane
29
$5,701
$197
Tamoxifen Citrate
76
$2,893
$38
Letrozole
17
$1,061
$62
Prochlorperazine Maleate
70
$785
$11
Dexamethasone
29
$631
$22
Ondansetron
25
$575
$23
Diphenoxylate-Atropine
13
$564
$43
Prednisone
57
$419
$7
Potassium Chloride
18
$224
$12
Lorazepam
20
$182
$9
2022: 11 drugs
Part D drugs prescribed in 2022
Erleada
33
$495,512
$15,016
Xtandi
56
$429,083
$7,662
Abiraterone Acetate
67
$82,779
$1,236
Exemestane
27
$9,331
$346
Anastrozole
188
$5,353
$28
Tamoxifen Citrate
60
$2,200
$37
Prednisone
86
$703
$8
Prochlorperazine Maleate
29
$409
$14
Dexamethasone
16
$385
$24
Venlafaxine Hcl Er
12
$323
$27
Ondansetron
16
$291
$18
2021: 14 drugs
Part D drugs prescribed in 2021
Xtandi
91
$812,572
$8,929
Erleada
28
$317,332
$11,333
Tagrisso
14
$214,714
$15,337
Abiraterone Acetate
92
$114,876
$1,249
Xarelto
15
$12,798
$853
Exemestane
34
$9,424
$277
Anastrozole
185
$5,510
$30
Tamoxifen Citrate
49
$2,437
$50
Prednisone
88
$738
$8
Ondansetron
33
$634
$19
Prochlorperazine Maleate
46
$633
$14
Dexamethasone
21
$494
$24
Hydrocodone-Acetaminophen
18
$319
$18
Potassium Chloride
12
$68
$6
2020: 17 drugs
Part D drugs prescribed in 2020
Xtandi
97
$998,774
$10,297
Tagrisso
25
$390,711
$15,628
Abiraterone Acetate
110
$304,531
$2,768
Rozlytrek
11
$195,842
$17,804
Exemestane
44
$17,929
$407
Xarelto
19
$10,695
$563
Anastrozole
159
$4,808
$30
Enoxaparin
11
$4,428
$403
Tamoxifen Citrate
57
$3,600
$63
Prednisone
106
$735
$7
Megestrol Acetate
18
$622
$35
Prochlorperazine Maleate
44
$585
$13
Dexamethasone
20
$559
$28
Ondansetron
21
$344
$16
Hydrocodone-Acetaminophen
17
$254
$15
Acyclovir
14
$212
$15
Lorazepam
19
$124
$7
2019: 18 drugs
Part D drugs prescribed in 2019
Xtandi
82
$809,219
$9,869
Abiraterone Acetate
107
$410,000
$3,832
Tagrisso
25
$380,119
$15,205
Zytiga
24
$257,898
$10,746
Afinitor
12
$184,578
$15,382
Exemestane
48
$20,840
$434
Enoxaparin
12
$4,570
$381
Anastrozole
129
$3,614
$28
Tamoxifen Citrate
61
$3,106
$51
Prednisone
121
$1,048
$9
Bicalutamide
14
$728
$52
Letrozole
16
$477
$30
Megestrol Acetate
14
$414
$30
Prochlorperazine Maleate
42
$364
$9
Ondansetron
12
$145
$12
Lorazepam
20
$145
$7
Dexamethasone
11
$136
$12
Hydrocodone-Acetaminophen
11
$133
$12
2018: 15 drugs
Part D drugs prescribed in 2018
Zytiga
109
$1,061,471
$9,738
Xtandi
50
$448,106
$8,962
Revlimid
11
$164,524
$14,957
Exemestane
38
$17,885
$471
Enoxaparin
14
$4,419
$316
Tamoxifen Citrate
58
$3,511
$61
Anastrozole
113
$3,231
$29
Prednisone
104
$805
$8
Prochlorperazine Maleate
30
$420
$14
Ondansetron
27
$412
$15
Megestrol Acetate
11
$389
$35
Dexamethasone
24
$375
$16
Lorazepam
54
$320
$6
Letrozole
15
$224
$15
Hydrocodone-Acetaminophen
13
$142
$11
2017: 20 drugs
Part D drugs prescribed in 2017
Zytiga
49
$438,428
$8,948
Xtandi
47
$384,059
$8,171
Revlimid
16
$204,702
$12,794
Afinitor
12
$168,051
$14,004
Ibrance
11
$116,674
$10,607
Exemestane
25
$16,537
$661
Enoxaparin
18
$6,583
$366
Oxycontin
18
$6,240
$347
Tamoxifen Citrate
71
$3,986
$56
Anastrozole
90
$2,606
$29
Bicalutamide
24
$1,006
$42
Ondansetron
37
$799
$22
Prednisone
72
$526
$7
Lorazepam
60
$497
$8
Letrozole
21
$386
$18
Dexamethasone
28
$334
$12
Prochlorperazine Maleate
43
$268
$6
Acyclovir
12
$267
$22
Hydrocodone-Acetaminophen
22
$211
$10
Citalopram Hbr
11
$66
$6
2016: 18 drugs
Part D drugs prescribed in 2016
Xtandi
53
$408,053
$7,699
Zytiga
19
$150,641
$7,928
Exemestane
37
$15,011
$406
Oxycodone Hcl Er
21
$7,187
$342
Oxycontin
18
$6,726
$374
Enoxaparin
12
$3,296
$275
Tamoxifen Citrate
58
$2,823
$49
Anastrozole
79
$2,131
$27
Lorazepam
74
$636
$9
Hydrocodone-Acetaminophen
25
$619
$25
Bicalutamide
13
$502
$39
Prednisone
41
$433
$11
Dexamethasone
33
$425
$13
Letrozole
23
$386
$17
Ondansetron
27
$323
$12
Prochlorperazine Maleate
41
$310
$8
Sulfamethoxazole-Trimethoprim
11
$196
$18
Acyclovir
11
$151
$14
2015: 19 drugs
Part D drugs prescribed in 2015
Xtandi
65
$507,938
$7,814
Zytiga
27
$212,735
$7,879
Exemestane
47
$19,846
$422
Enoxaparin
13
$7,130
$548
Oxycontin
15
$5,023
$335
Oxycodone Hcl Er
11
$4,034
$367
Tamoxifen Citrate
67
$3,297
$49
Anastrozole
87
$1,975
$23
Bicalutamide
11
$753
$68
Hydrocodone-Acetaminophen
31
$693
$22
Ondansetron
18
$439
$24
Dexamethasone
38
$402
$11
Prednisone
41
$370
$9
Zolpidem
13
$350
$27
Lorazepam
56
$323
$6
Prochlorperazine Maleate
44
$252
$6
Letrozole
22
$182
$8
Gabapentin
17
$138
$8
Acyclovir
16
$120
$7
2014: 21 drugs
Part D drugs prescribed in 2014
Xtandi
26
$207,324
$7,974
Zytiga
27
$181,350
$6,717
Exemestane
55
$21,532
$391
Enoxaparin
12
$9,425
$785
Oxycontin
22
$6,848
$311
Anastrozole
98
$3,805
$39
Tamoxifen Citrate
56
$2,527
$45
Ketoconazole
12
$1,192
$99
Bicalutamide
19
$1,130
$59
Hydrocodone-Acetaminophen
40
$682
$17
Hydrocortisone
12
$476
$40
Prednisone
35
$403
$12
Dexamethasone
35
$329
$9
Letrozole
11
$309
$28
Ondansetron
14
$267
$19
Prochlorperazine Maleate
36
$243
$7
Lorazepam
38
$218
$6
Zolpidem
18
$123
$7
Acyclovir
11
$123
$11
Gabapentin
11
$113
$10
Promethazine
11
$96
$9
2013: 18 drugs
Part D drugs prescribed in 2013
Zytiga
37
$233,945
$6,323
Xtandi
11
$86,248
$7,841
Exemestane
52
$16,740
$322
Enoxaparin
15
$16,082
$1,072
Anastrozole
134
$7,652
$57
Tamoxifen Citrate
50
$1,431
$29
Ketoconazole
14
$1,032
$74
Ondansetron
31
$703
$23
Hydrocodone-Acetaminophen
71
$576
$8
Hydrocortisone
13
$516
$40
Letrozole
12
$389
$32
Megestrol Acetate
11
$368
$33
Dexamethasone
36
$279
$8
Lorazepam
38
$255
$7
Promethazine
26
$243
$9
Prednisone
42
$214
$5
Ciprofloxacin
11
$53
$5
Atenolol
12
$42
$4
Money from drug and device companies
$1,157 in 2025
Industry payments by year
2025
4
8
$890
$1,157
2024
3
5
—None
$262
2023
1
2
—None
$35
2021
3
3
—None
$34
2019
2
2
—None
$24
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
Research payments by company and study
Novartis Pharmaceuticals Corporation · A Phase Iiib Study To Characterize the Effectiveness and Safety of Adjuvant Ribociclib in A Wide Patient Population With Hr+ Her2- Early Breast Cancer (Adjuvant Wider) · 2025
Their institution
$98,190
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cancer · 2019
Their institution
$56,750
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cance · 2020
Their institution
$42,850
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cancer · 2024
Their institution
$9,100
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cancer Wi203696 · 2025
Their institution
$7,883
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cance · 2021
Their institution
$7,700
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cancer Wi203696 · 2023
Their institution
$4,700
PFIZER INC. · Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hr Or Her2 Early Breast Cance · 2022
Their institution
$4,100
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2020
Their institution
$96
Professional record
NPI
1215948484
Licence
CA A72747California A72747: Current · expires 2027-10-31